- Benzinga
HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer
HUTCHMED (China) Limited (NASDAQ: HCM) announced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022. The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared
- AASTOCKS
《大行報告》滙豐研究上調和黃醫藥(HCM.LN)目標價至3.2英鎊 評級「買入」
滙豐研究發表報告，對和黃醫藥(HCM.LN)腫瘤藥銷售增長持樂觀態度，目標價由3英鎊升至3.2英鎊，評級「買入」。 報告指，和黃醫藥的腫瘤藥上半年銷售額為9,100萬美元，按年增長113%，與該行預期一致。該行預計，在市場份額增加、納入NRDL、新藥上市和適應症擴大的推動下，增長趨勢將持續。
- Yahoo財經專欄
真知焯見│大市缺乏資金追捧 反彈難持久（關焯照）
大家不妨利用衍生工具，例如窩輪、牛熊證、期指等，來炒賣港股。然而，由於衍生工具涉及槓桿，散戶在注碼上一定要克制，目的只是以小博大，切勿下重注，否則很容易輸身家。
